Trial Profile
A randomized phase III trial of Gemzar [gemcitabine] versus Doxil [doxorubicin liposomal] with crossover treatment option for patients with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer undergoing second or third-line chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- 28 Oct 2005 New trial record.